



1616

RECEIVED
MAY 16 2003

TECHNICAL CENTER 1600/2900

613
VCS
5-21-3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: P. RUBIN

Application No.: 10/084,250

Group Art Unit: 1616

Filed: February 28, 2002

Examiner: M. Haghighatian

For: METHODS AND COMPOSITIONS
USING NORASTEMIZOLE IN
COMBINATION WITH LEUKOTRIENE
INHIBITORS

Attorney Docket No.: 4821-469

AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Office Action dated February 24, 2003, Applicant submits the following remarks for entry into the record and consideration by the Examiner.

IN THE CLAIMS

Please rewrite claims 30-36, 38, and 40 as follows:

-
31. (Amended) The method of claim ¹12 or ²13, wherein the amount of norastemizole administered is from about 10 mg to about 100 mg per day.
32. (Amended) The method of claim ¹12 or ²13, wherein the compositions are administered as a nasal or oral spray.
33. (Amended) The method of claim ¹12 or ²13, wherein at least one of the norastemizole and the leukotriene inhibitor is administered as a nasal or oral spray.
34. (Amended) The method of claim ¹12 or ²13, wherein at least one of the norastemizole and the leukotriene inhibitor is administered in an oral solid dosage form.
35. (Amended) The method of claim ³14, wherein the norastemizole is administered as a nasal or oral spray.
36. (Amended) The method of claim ¹12 or ²13, wherein the leukotriene inhibitor is a 5-lipoxygenase inhibitor.
-